Clinical trial · Observational
Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Because of economic issue, we could just enrolled total 150 patients.
Summary
Brief summary (as posted)
Aromatase(CYP19)inhibitor is one of the major antihormonal drug for breast cancer in postmenopausal women. The variation of CYP19 may affect the effect of aromatase inhibitor. However, the incidence of variation of CYP19 in Korea has not known. Therefore, the investigators want to know the incidence of variation of CYP19 and to assess the effect of these variations of CYP19 to aromatase inhibitor users.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Aromatase Inhibitor | — | UNRESOLVED | — |
| CYP19 | — | UNRESOLVED | — |
| Polymorphism | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- SMAC (SMc AI user Cohort)
- description
- All patients who took the AI (Aromatase inhibitor)will be enrolled
Primary outcomes (1)
- measure
- The prevalence of CYP19 polymorphism
- timeFrame
- 12. 31. 2011
Secondary outcomes (1)
- measure
- The effect of CYP19 polymorphism to the prognosis of AI user
- timeFrame
- 12. 31. 2016
Eligibility
Eligibility (as posted)
- Sex
- Female
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * hormone receptor positiveBreast cancer patient * postmenopausal women * first user of aromatase inhibitor Exclusion Criteria: * premenopausal * The patient who take the other antihormonal therapy * osteoporosis patients
References
Publications (0)
Data not yet available